相关实验视频
Updated: Jan 9, 2026

16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
36.0K
在晚期病中植入左心室辅助装置
Benjamin N French1, Anudeep S Nakirikanti1, Ian Kusher1
1Emory University School of Medicine, Atlanta, GA.
JHLT open
|December 1, 2025
概括
患有晚期慢性病 (CKD) 的患者在HeartMate 3左心室辅助装置 (LVAD) 植入后的早期生存率较低. 然而,1年和2年的长期存活率与没有晚期CKD的患者相似.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 医疗器械 医疗器械
背景情况:
- 晚期慢性病 (CKD) 通常是左心室辅助器件 (LVAD) 植入的禁忌.
- 对于晚期CKD患者的HeartMate 3 LVAD结局存在有限的数据.
研究的目的:
- 评估HeartMate 3 LVAD植入在晚期CKD患者中的结果.
- 为了比较患有或没有晚期CKD的患者之间的存活率和脏替代疗法 (RRT) 率.
主要方法:
- 对193名接受了HeartMate 3 LVAD植入的患者进行了回顾性审查.
- 基于手术前估计的球过率 (eGFR) 的患者分层:≥30mL/min/1.73m2 (对照组) 与<30 (晚期病).
- 对存活率和植入后需要RRT的分析.
主要成果:
- 与对照组相比,30天的早期存活率在晚期病患者 (84.6%) 中较低 (94.2%,p=0.04).
- 1年 (79.5% vs. 79.9%,p=0.87) 和2年 (73.9% vs. 68.7%,p=0.60) 的存活率没有显著差异.
- 植入后的RRT在30.3%的晚期病患者中需要进行,而对照组中只有18.2% (p=0.18).
结论:
- 尽管早期死亡率较高,但晚期CKD患者在HeartMate 3 LVAD植入后实现了可比的1年和2年生存期.
- 在精心挑选的晚期CKD患者中,LVAD植入可能是可行的选择.
- 需要进一步的研究来优化选择标准和管理策略.
相关概念视频
Cardiomyopathy V: Interprofessional Care
314
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
314
Kidney Transplant I: Introduction
310
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
310
Heart Failure VI: Adjunct Therapies
235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235
Cardiomyopathy II: Dilated Cardiomyopathy
447
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
447
Kidney Transplant II: Surgical Procedure
289
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
289
Hemodialysis II: Procedure and Complications
573
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
573

